Silver Book Fact

Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord injury.

Cardenas, Diana D, Edward C Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M Scavone, Makota M Suzuki, and Lloyd E Knapp. A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury. Neurology. 2013; 80(6): 533-9. http://www.neurology.org/content/early/2013/01/23/WNL.0b013e318281546b.abstract

Reference

Title
A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury
Publication
Neurology
Publication Date
2013
Authors
Cardenas, Diana D, Edward C Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M Scavone, Makota M Suzuki, and Lloyd E Knapp
Volume & Issue
Volume 80, Issue 6
Pages
533-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.  
  • The use of sodium oxybate (SXB) in fibromylagia patients reduced pain by 30% or more in 54-58% of patients (versus 35.2% for placebo). SXB also reduced fatigue and sleep disturbance.  
  • A biopsychosocial approach (i.e., one that takes into account physical, emotional, and environmental factors in the assessment and treatment of pain) has been found to improve the pain care of…  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Advances in neuroimaging will continue to offer information on the brain’s functioning and how it correlates to the pain experience.